Program Goals Overview Glatiramer Acetate 3 Times a Week.

Slides:



Advertisements
Similar presentations
Dimethyl Fumarate and Peginterferon b-1a: New Insights Into the Pivotal Trials Pavan Bhargava, MD Johns Hopkins University School of Medicine, Baltimore,
Advertisements

Bladder Cancer: A New Era in Treatment
Perspectives on Managing Polycythemia Vera for the Nurse Practitioner and Physician Assistant.
Why New Treatments for Schizophrenia Should Be on Your Radar
Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.
Program Goals Teriflunomide: Pooled Safety Data.
Goals of Therapy for Patients With UC
Optimizing Use of Biological Agents in Ulcerative Colitis
Introducing JAK Inhibitors in Rheumatoid Arthritis
Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.
The Changing Therapeutic Landscape of CINV
Current Controversies in Multiple Sclerosis Management
Emergency Management of NOAC Bleeding
Charting Progress in MS Diagnosis and Treatment for Today and Tomorrow
Emerging Data and Clinical Advances in MS:
The HCV Revolution: Are You and Your Practice Ready?
Cancer Stem Cell Therapies in Gastrointestinal Cancers
SGLT2 Inhibitors in Phase 3 Trials
Definitions: Seizure, Epilepsy, Epilepsy Syndrome
What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?
Program Goals. The Role of Chemotherapy in Improving Quality of Life in Advanced NSCLC.
Challenges in Managing Progressive Multiple Sclerosis
GLP-1 Receptor Agonists: How Early Is Appropriate?
What Is a Biosimilar?. Biosimilar Application in RA Clinical Practice: Current Knowledge and New Data  
Oral vs IV High-Dose Methylprednisolone Are Equally Effective in MS
Are We Closer to Personalized Medicine in MS?
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.
Integrated Diabetes Care: How Can We Make the Best Use of New Technology?
Patient Case: KC. Optimizing Treatment of Mild to Moderate Ulcerative Colitis: A Case-Based Perspective.
New Agents, New Regimens, New Strategies
EHL Technologies in Hemophilia Care
Navigating New Oral Treatment Algorithms in CLL
Program Goals Disclaimer Overview Assessing Disease Activity.
Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors
Oral Anticoagulation in AF
Essential Concepts in the Use of Immunotherapies in Bladder Cancer
Biosimilars in Hematologic Oncology
Charting Progress in MS Treatment:
Perspectives on the Impact of Inflammation in OA
ADVANCED PARKINSON'S DISEASE:
Case: A 28-Year-Old Man. When a 5-ASA Agent No Longer Maintains Remission in a Patient With Ulcerative Colitis.
Personalized Therapy in Relapsed or Refractory CLL
Advancing the Treatment of IBD With Biologics
Health Strategies Group
Program Goals. Technological Advances in Longer-Acting Factor Replacement Therapy for Hemophilia.
The Evolving Treatment Landscape in Atopic Dermatitis
Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.
What Does It Take to Be a Long-Acting Replacement Therapy in Hemophilia A?
What's New in Therapeutic Options for Moderate to Severe RA?
Advances in Immunotherapy for Peanut Allergy
Battling the Flu: Latest Advances in the Influenza Treatment Arsenal
CAD and HF Often Coexist
IgG-Fc Fusion Proteins and Immunomodulation: What Does the Science Tell Us?
Implications of Emerging Treatments for Beta-Thalassemia
New European Anticoagulant Approvals Will They Affect Practical Guidance?
Critical Decision Points in Insomnia
Application of Biologics in IBD:
Incorporating Prostacyclins Into Practice
Essential Updates for PsA: A Complex Disease to Manage
Program Goals Overview Natalizumab Natalizumab: Recent Label Changes.
Clinical Challenges and Updates in Managing Seizure Clusters
Program Goal. Program Goal Disclaimer Overview.
Oral Therapies in MS.
AMD Therapy: Where Are We Now and Where Are We Going?
Tailoring Therapy in the Newly Diagnosed Patient With CLL
Would Patients With Hemophilia B Benefit From Switching to Extended Half-Life Factor Products? 
Targeting IL-23 for Therapeutic Longevity in Psoriasis
Fixed-Ratio Combination Therapy in T2DM
Treatment Advances for RA
In the Know.
Presentation transcript:

Program Goals

Overview

Glatiramer Acetate 3 Times a Week

Glatiramer Acetate 3 Times a Week (cont)

Glatiramer Acetate 3 Times a Week (cont): Safety

Glatiramer Acetate: Generic Formulation

Pegylated Interferon for MS

Pegylated Interferon (cont): Pharmacokinetics

Pegylated Interferon (cont): ADVANCE Phase 3 Study

Clinical Impact of New Injectable Formulations

Oral Therapies for MS

Oral Therapies: Mechanisms

Oral Therapies: Efficacy

Oral Therapies: Safety

Oral vs Standard Therapies

Considerations in Selecting Oral Therapy

Switching to an Oral Agent: Counseling Considerations

Switching to an Oral Agent: Is a Washout Period Necessary?

Looking Ahead

Looking Ahead (cont)

Summary and Key Points

Abbreviations

References

References (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.